Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Valine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.79 |
| ▸ | LAP3 | P28838 | 4/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | GLUL | P15104 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL1758768 | 1.00 | SLC7A5 (0.79) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL29415345 | 1.00 | SLC7A5 (0.79) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL16010343 | 1.00 | SLC7A5 (0.79) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL11539550 | 0.90 | SLC7A5 (0.71) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL8516 | 0.89 | — | — | |
| Valine SCHEMBL8515 | 0.89 | — | — | |
| Valine SCHEMBL288203 | 0.89 | SLC7A5 (1.00) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL1813972 | 0.89 | SLC7A5 (1.00) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL41225 | 0.89 | SLC7A5 (1.00) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL2785563 | 0.89 | SLC7A5 (1.00) | SLC7A5LAP3SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101953848-B | Medicament for treating cancer and application thereof | PANZHIHUA XINGCHEN VANADIUM & TITANIUM CO LTD | 2011-12-21 | — | — | CN | claimed |
| CN-101972273-A | Application of medicine in preparing medicines for treating diabetes mellitus | PANZHIHUA XINGCHEN VANADIUM & TITANIUM CO LTD | 2011-02-16 | — | — | CN | claimed |
| CN-101953848-A | Medicament for treating cancer and application thereof | PANZHIHUA XINGCHEN VANADIUM & TITANIUM CO LTD | 2011-01-26 | — | — | CN | claimed |
| JP-3033834-A | — | — | None | — | — | JP | disclosed |
| JP-55066597-A | — | — | None | — | — | JP | disclosed |
| WO-2024002353-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | 江苏恒瑞医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | NuCana plc (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3224268-B1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2019-06-26 | — | — | EP | disclosed |
| CN-109806620-A | The chromatography separating method and quantitative detecting method of progesterone intermediate II and progesterone intermediate I | 湖南成大生物科技有限公司 | 2019-05-28 | — | — | CN | disclosed |
| WO-2005004714-A1 | METHOD AND APPARATUS FOR DIAGNOSING BONE TISSUE CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-01-20 | — | — | WO | disclosed |
| US-5830871-A | Inhibitors of E-, P- and L-selectin binding | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-11-03 | — | — | US | disclosed |
| US-5571799-A | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response | BASCO, LTD. (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1993003733-A1 | SYNTHESES, PHARMACEUTICAL COMPOSITION AND METHOD OF APPLICATION OF (2'-5') OLIGOADENYLATE ANALOGUES | BASCO, LTD. (US) | 1993-03-04 | — | — | WO | disclosed |
| JP-H0333834-A | ORGANIC NONLINEAR OPTICAL MATERIAL | HOYA CORP | 1991-02-14 | — | — | JP | disclosed |
| US-4874779-A | Mitomycin phosphate derivatives | BRISTOL-MYERS COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4246169-A | Flammable plastics containing a flame retardant amount of polyarylphosphates and the polyarylphosphates | FMC CORPORATION (US) | 1981-01-20 | — | — | US | disclosed |
| JP-S5566597-A | AMINOPHOSPHORIC ACID SALT DERIVED FROM CYCLIC PHOSPHORIC ACID SALT AND AMINO ACID | PORIHOSU KAGAKU KENKYUSHO:KK | 1980-05-20 | — | — | JP | disclosed |
| EP-0005053-A2 | Flame-retardant organic phosphates, their production, and compositions containing them | FMC Corporation (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | SLC7A5 600/4885LAP3 1813/4885SLC1A3 1180/4885 |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | MTAP, RNMT, ADA | SLC7A5 600/4885LAP3 1813/4885SLC1A3 1180/4885 |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SLC7A5 621/4885LAP3 1853/4885SLC1A3 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.